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Abstract 
Surface modifications of poly(lactide-co-glycolide) microparticles with different 
polycationic electrolytes have mainly been studied for conjugation to antigens and/or 
adjuvants. However, the in vivo immunological effects of using surface charged particles 
have not been address yet. In this study, microparticles were coated or not with 
protamine, a cationic and arginine-rich electrolyte that confers microparticles with a 
positively surface charge. We then evaluated the potential of protamine-coatings to 
assist the induction of immune responses in mice. Interestingly, enhanced antibodies 
and T-cell responses were observed in mice treated with the coated particles. In vitro 
studies suggested that the improved immunological performance was mediated by an 
increased uptake. Indeed, protamine-coated particles that carried a plasmid were even 
internalised into non-phagocytic cells and to cause their transfection. These results 
open the way for further research into a novel technology that combines the use 
protamine for facilitated cell penetration of that and biodegradable microparticles for 
prolonged antigen or drug release. 
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1. Introduction 
Polymeric biodegradable microparticles have been widely studied for a broad variety of 
pharmaceutical and biomedical applications [1], [2] and [3]. Commonly used 
poly(lactide-co-glycolide) (PLGA) types are available in medical grade and approved for 
use in humans, which makes them attractive for developing new drug and antigen 
delivery systems [4], [5] and [6]. With a size range similar to that of microorganisms, 
polymeric particles can be easily taken up by antigen-presenting cells (APCs) [7], a 
process that enables potent cellular as well as humoral immune responses [8], [9], [10], 
[11] and [12].  
Physico-chemical properties such as the molecular weight and monomer composition of 
the polymer, and the size and surface charge of the microparticles determine the 
antigen release rate [12] and may also affect the type of immune response elicited by 
the delivery system [6] and [13]. To add further flexibility and control of antigen and 
adjuvant delivery, the surface properties of PLGA microparticles have been modified 
[14], [15] and [16]. Surface modifications have been achieved with anionic electrolytes 
such as sodium dioctylsulfosuccinate [17] and [18] and cationic electrolytes such as 
chitosan, poly(ethylene imine), or protamine [14], [15], [16] and [19]. Protamine belongs 
to a group of low molecular weight (MW: 4000–4250 Da), arginine-rich, basic proteins, 
which condense DNA in the nucleus and are involved in spermatogenesis [20]. 
Protamine is a FDA-approved compound, which has found applications in, e.g., 
stabilising DNA [21], insulin complexation and formulation, and in reverting the 
anticoagulant effect of heparin [22], [23] and [24]. Protamine has been combined into 
PLGA microparticles [14] and [26] and used as a coating agent to bind nucleic acid on 
the surface of controlled-release particles [27], and on one occasion, the use of 
protamine-containing PLGA microparticles in mice is reported [25]. 
The aim of this study was to evaluate the properties of protamine-coated PLGA 
microparticles with regard to particle uptake in cells, transfection of cells, antigen 
presentation, and the induction of T-cell and antibody responses in mice. Interestingly, 
the protamine coating enhanced particle uptake even by non-phagocytic cells and 
promoted the stimulation of much stronger immune responses as compared to 
uncoated particles. 
2. Materials and methods 
2.1. Materials 
Purified phospholipase A2 (PLA2) from bee venom and chicken egg albumin (OVA; 
grade V) were purchased from Sigma-Aldrich (Buchs, Switzerland), and soy bean 
lecithin (Epikuron 200) from Degussa (Hamburg, Germany). Phosphorothioate-modified 
CpG oligodeoxynucleotide 1668 pt (5′-TCC-ATG-ACG-TTC-CCT-GAC-GTT-3′) was 
synthesised by Microsynth (Balgach, Switzerland). The 35 kDa poly(lactide-co-
glycolide) (PLGA 50:50) with uncapped end-groups (Resomer RG503H) was from 
Boehringer-Ingelheim (Ingelheim, Germany). Protamine sulphate from salmon, 
poly(vinyl alcohol) (PVA; Mowiol 4-88) and dichloromethane (DCM) were from Fluka 
(Buchs, Switzerland). The GFP plasmid (pmaxFP-Green-C) was provided by Amaxa 
(Cologne, Germany). 
2.2. Mice 
BALB/c, CBA/J and C57BL/6 mice were purchased from Harlan (Horst, The 
Netherlands) and used at 6–10 weeks of age. DO11.10 mice were generously provided 
by Martin F. Bachmann (Cytos Biotechnology, Switzerland) and are transgenic for the 
T-cell receptor recognising the OVA323–339 epitope on a 2Hd MHC-class II context in a 
BALB/c background [29]. OT-II mice were generously provided by Tobias Suter 
(University of Zurich, Switzerland). Also these mice are transgenic for the T-cell receptor 
recognising the OVA323–339 epitope but on a C57BL/6 (2Hb MHC II) background [30]. All 
mice experiments were approved and performed according to guidelines formulated by 
the Veterinary authorities of the canton of Zurich, and the mice were kept in a specific 
pathogen free (SPF) environment. 
2.3. Microparticle preparation 
PLGA microparticles were made by microextrusion-based w/o/w-solvent extraction 
using a static multilamination type micromixer (Institut für Mikrotechnik Mainz, Mainz, 
Germany), as previously described [28], with slight modifications. Three groups of 
formulations with different loads were prepared, with and without a protamine coating on 
the surface (Table 1). In the first group of microparticles, PLA2 was encapsulated for 
later evaluation of humoral responses. Briefly, 2 mg of PLA2 was dissolved in 100 μl 
water and emulsified on ice (ultrasonication with a probe for 10 s; 40% amplitude, 
UP200H, Hielscher Ultrasonics, Teltow, Germany) into 0.6 g of PLGA dissolved in DCM 
(5%, w/w). This w/o-emulsion was extruded through the micromixer along with a 0.5% 
(w/w) PVA aqueous solution as extraction phase; the resulting suspension of 
microparticles was collected using the same aqueous solution of 0.5% (w/w) PVA for 
further solvent extraction and evaporation. To obtain positively charged microparticle 
coating, 0.5% (w/w) protamine solution was used as first extraction phase and water as 
final collection fluid. The particles were gently stirred using a magnetic rod and kept 
under laminar air-flow for 30 min for further solvent removal and hardening. Finally, the 
microparticles were collected on a mixed cellulose ester membrane filter with a pore 
size of 0.8 μm (Whatman, Dassel, Germany) and dried at 20 mbar and at room 
temperature for 24 h. 
Table 1.  
Microparticle formulations 
Test 
formulation 
Zeta 
potential 
(mV) 
Size distribution 
(μm) (D10/D50/D90) 
Antigen 
loading 
(μg/mg MP) 
Study application 
pGFP-MP − 11.8 ± 0.8 1.6/3.2/5.2 0.76 Particle uptake and 
transfection 
pGFP-
MP/protamine 
64.8 ± 4.3 1.9/3.5/5.3 0.76  
OVA-MP − 11.6 ± 0.1 1.4/3.2/6.4 37.9 Antigen 
presentation and T 
cell response 
OVA-
MP/protamine 
19.3 ± 0.6 2.3/7.2/20.9 37.9  
PLA2-MP − 2.4 ± 4.2 1.2/4.4/24.9 0.84 B-cell responses 
PLA2-
MP/protamine 
10.5 ± 6.6 3.0/6.8/15.5 0.77  
Characteristics and application of the different groups of formulations used in the 
current the study. 
 
The second group of microparticles, with and without protamine coating, contained 
pGFP. They were prepared for analysing particle uptake by cells and particle-mediated 
cell transfection. Briefly, pGFP (0.7 mg) was dissolved in Tris–EDTA (TE) buffer (0.2 ml) 
and emulsified in PLGA (0.2 g) dissolved in DCM (5%, w/w). The subsequent steps for 
microparticle formation were as described above. 
The third group of microparticles, with and without protamine coating, was loaded with 
OVA for subsequently analyses of T-cell responses. Briefly, OVA (50 mg) was dissolved 
in PBS (0.8 ml), emulsified in PLGA (1 g) dissolved in DCM (5%, w/w), and further 
processed as described above. 
2.4. Particle size and zeta potential measurements 
Microparticle size distributions were determined by laser light diffraction (Mastersizer X, 
Malvern Instruments Malvern, United Kingdom) with a suspension of approx. 1 mg of 
dry microparticles in distilled water. A volume-weighted size distribution with 10%, 50% 
and 90% undersize diameters (D10, D50 and D90) was determined. The surface charge of 
the microparticles was determined by zeta potential measurement (Zetasizer 3000 HAS, 
Malvern Instruments). Dry microparticles (0.2 mg) were suspended in 1 mM KCl (2 ml; 
pH = 7.6), and the mean zeta potential value was calculated from two samples per 
batch and triplicate analysis per sample. 
2.5. Determination of antigen content in the microparticles 
Triplicates of approx. 7 mg PLA2- or pGFP-containing particles were dissolved in 0.5 ml 
chloroform and the protein or the plasmid extracted from the organic phase by mixing 
with 0.2 ml Tris–HCl buffer and subsequent centrifugation at 3000 rpm for 3 min. The 
content of plasmid DNA from the pGFP-MPs was analysed by the PicoGreen 
quantification kit (Invitrogen AG, Switzerland) following the manufacturer instructions. 
The PLA2 concentration in the aqueous extract was analysed by an ELISA inhibition 
assay. Briefly, 60 μl of the Tris–HCl phase containing the extracted PLA2 was mixed in 
a 96-well plate with 60 μl human anti-PLA2 serum diluted (1:25) in phosphate-buffered 
saline containing 0.05% Tween20 and 2.5% skimmed dry milk (PBSTM). In parallel, 
serial dilutions of PLA2 were mixed with sensitised serum and utilised as a standard for 
quantification. After 2 h of incubation at 37 °C, 100 μl of each sample was transferred to 
an ELISA plate that was pre-coated with 5 μg/ml PLA2 at 4 °C overnight and 
subsequently blocked with PBSTM at room temperature for 1 h. After 2 h incubation at 
37 °C, the plate was washed and incubated with horseradish peroxidase-conjugated 
anti-human IgG (BD Biosciences Pharmingen, San Diego, CA). The plate was washed 
and developed with 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) diammonium 
salt (Sigma-Aldrich) in 1 M sodium dihydrogen phosphate and the absorption was read 
at 405 nm using a plate reader. The loading efficiency of PLA2 in the MP was calculated 
relative to the theoretical maximum loading value. For the quantification of OVA inside 
the MPs, OVA-containing particles were dissolved in 0.1 M NaOH and 5% SDS 
overnight at room temperature and then measured by the BCA protein assay (Pierce 
Biotechnology, USA). 
2.6. Internalisation of pGFP-loaded PLGA microparticles (MP) by HEK cells 
The role of the protamine in the particle uptake by cells was studied by measuring the 
transfection of Human Embryonic Kidney (HEK) cells upon incubation with 
microparticles containing the plasmid pGFP, taking use of the fact that positive 
transfection would necessarily imply uptake of the plasmid containing particle by the 
cell; preliminary studies with FITC or coumarin-loaded particles were also done, but this 
did not allow to clearly distinguish between internalised particle and particle attached to 
the cell surface. Cells were seeded in 24-well plates pre-coated with poly-d-lysine at a 
density of 3 × 105 per well. One day after seeding, 50, 100 or 200 μg of pGFP-MP or 
pGFP-MP/protamine were added to the cells in duplicates; after incubation for 4 h and 
various subsequent washes, the cells were incubated with fresh complete medium. The 
transfection of cells was monitored for two further weeks using a Zeiss Axiovert 
fluorescence microscope (Carl Zeiss, Jena, Germany). The average number of 
transfected (green) cells in 10 randomly selected bright light fields was counted. 
2.7. In vitro analysis of T-cell stimulation 
Murine dendritic cells were isolated from BALB/c bone-marrow and grown in 10 cm Petri 
dishes at a density of 1 × 106 cell/ml in 10 ml RPMI-1640 complete media containing 
20 ng/ml of granulocyte macrophage colony stimulating factor (GM-CSF) and 10 ng/ml 
of IL-4 (Immunotools, Friesoythe, Germany). After 2 and 4 days, the culture medium 
was replaced by fresh medium containing GM-CSF and IL-4. After 6 days, immature 
DCs were collected and seeded at 1 × 105 cells per well in a 96-well plate and then 
pulsed for 3 h at 37 °C and 5% CO2 with escalating amounts of OVA-containing 
microparticles, empty microparticles (1 or 100 μg) or aqueous OVA (10 or 100 μg/ml). 
After three washing steps, the cells were co-cultured with splenocytes (1 × 105 
cells/well) from DO11.10 mice. After 20 and 48 h, aliquots of the supernatant were 
taken for determination of IL-2 and IFN-γ secretion, respectively. Lymphocyte 
proliferation was measured after 48 h by [3H] thymidine (1 μCi/well) incorporation during 
the last 16 h of culture using a 1450-MicroBeta TriLux liquid scintillation counter 
(Wallac, Finnland). 
2.8. Immunisation of mice 
To evaluate the potential of the microparticles to stimulate T-cell responses in vivo, 6–
10 week old female OT-II mice were used. The mice were injected with 1 mg of OVA-
MP or similar particles coated with protamine (OVA-MP/protamine); for injection, the 
microparticles were suspended in 1% aqueous lecithin solution. Blood was withdrawn at 
different time points (7, 14 and 21 days), and the lymphocytes analysed by flow 
cytometry for IFN-γ producing cells. 
For the study of antibody responses, PLA2-containing microparticle formulations were 
tested in 6–10 weeks old female CBA/J mice. The formulations PLA2-MP or PLA2-
MP/protamine were suspended in 1% aqueous lecithin solution prior to subcutaneous 
injection of a particle dose equivalent to 1 μg of entrapped PLA2; 1.2–1.3 mg of 
microparticles were injected in a volume of 150 μl. The mice were boosted with the 
same preparation and dose after 28 days. Serum was prepared from blood taken on 
days 28, 55 and 84 and frozen at − 20 °C until analysed by ELISA. Additional two 
groups of mice were injected with the same two formulations PLA2-MP or PLA2-
MP/protamine after addition of 3.1 nmol CpG. 
2.9. Flow cytometry 
Intracellular IFN-γ was assessed in blood of the OT-II mice injected with 1 mg of OVA-
MP or OVA-MP/protamine. After lysis of the erythrocytes with hypotonic Red Blood Cell 
Lysis Buffer (Sigma-Aldrich), splenocytes were stimulated in vitro with soluble OVA 
(10 μg/ml) and brefeldin A (10 μg/ml) (Sigma-Aldrich) for 3 h at 37 °C and 5% CO2. For 
FACS staining, the cells were washed several times, incubated with anti-CD16/CD32 for 
Fc-receptor blocking (5 min), and stained with anti-CD44-FITC and anti-CD4-APC 
antibodies for 30 min. Cells were then fixed with 1% paraformaldehyde for 10 min and 
subsequently stained with anti-IFN-γ-PE in PBS/0.5% saponin for 30 min. All stainings 
were done in PBS/2% FCS at 4 °C, unless specified otherwise, and all antibodies were 
purchased from BD Pharmingen (Franklin Lakes, NJ, USA). Samples were measured 
on a FACSCalibur flow cytometer (BD Bioscience, San Jose, CA, USA), and data was 
analysed using FlowJo software (Ashland, OR, USA). 
2.10. Antibody determination by enzyme-linked immunosorbent assay (ELISA) 
For detection of PLA2 antibodies, microtitre 96-well plates (Nunc Maxisorb, Wiesbaden, 
Germany) were coated with 5 μg/ml PLA2 in carbonate buffer at 4 °C overnight. The 
plates were blocked with 2.5% skinned dry milk in phosphate-buffered saline containing 
0.05% Tween 20 (Serva, Heidelberg, Germany) (PBSTM) for 1 h. Then, serial dilutions 
of individual mice sera in PBSTM were incubated in the plates for 2 h. Next, the plates 
were incubated with 1 μg/ml biotinylated goat anti-mouse IgG1 or IgG2a (BD Bioscience 
Pharmingen) in PBSTM for 2 h. Subsequently, plates were incubated with a 1:1000 
dilution of streptavidin-conjugated horseradish peroxidase (BD Pharmingen) for 1 h and 
developed with the enzyme substrate 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic 
acid) diammonium salt (Sigma-Aldrich) in 1 M sodium dihydrogenphosphate. The 
endpoint optical density was measured at 405 nm after 20 min incubation using a 
microplate reader Model 550 (BioRad, Hercules, CA, USA). All steps were intercepted 
by washings with PBST. 
3. Results 
3.1. Microparticle characterisation 
Three different groups of microparticles, all with and without protamine coating, were 
prepared (Table 1). The formulations with encapsulated pGFP, named pGFP-MP or 
pGFP-MP/protamine, had a very similar size distribution. Fifty percent of the particles 
were smaller than 3.2 μm or 3.5 μm, respectively. For both OVA- and PLA2-containing 
formulations, the size of the protamine-coated particles was larger than that of the non-
coated particles. This was most evident for the OVA-containing microparticles, where 
50% of the OVA-MP/protamine were smaller than 7.2 μm as compared to 3.2 μm for the 
non-coated particles (Table 1). Independent of the encapsulated antigen, the zeta 
potential of the protamine-coated microparticles was, as expected, positive (+ 11 to 
+ 65 mV), which is due to the polycationic charge of protamine; on the contrary, the 
non-coated particles had negative zeta potential (ranging from − 11.8 to − 2.4 mV). 
3.2. In vitro internalisation of pGFP-loaded microparticles 
To examine the effect of the protamine coating on the internalisation of the 
microparticles, HEK cells were incubated for 4 h with different amounts of pGFP-
containing particles, with or without protamine coating. Transfection of the cells was 
assessed as a measure for particle internalisation by fluorescence microscopy. As 
illustrated in Fig. 1A, only protamine-coated particles were able to transfect HEK cells. 
The transfection was dose-dependent, as the efficacy increased with the amount of 
particles used in the culture (Fig. 1B) and the frequency of transfected cells was approx. 
0.4% (0.1–1.0%). 
 
 
 
Fig. 1. Internalisation of microparticles containing pGFP by HEK cells. (A) Fluorescence 
microscopy pictures of cells incubated with 100 μg of protamine-coated or uncoated 
microparticles. (B) Quantification of positive cells as assessed by counting the green 
cells in 10 bright randomly selected light fields per well, after 72 h of incubation with the 
microparticles. The data is representative of three similar experiments. 
 
3.3. In vitro proliferation of specific T cells 
To assess the role of the protamine coating in the presentation of encapsulated antigen, 
OVA-containing microparticles, with and without protamine coating, were incubated at 
escalating amounts with bone-marrow derived DCs from BALB/c mice. The pulsed DCs 
were then co-cultured with splenocytes derived from transgenic DO11.10 mice. After 
20 h, the secretion of IL-2 in the supernatant was measured by ELISA and after 48 h 
proliferation was determined by measuring the [3H] thymidine incorporation. Fig. 2A 
reveals that the protamine coating enhanced the IL-2 secretion in a dose-dependent 
manner and with a 10-fold higher sensitivity than the uncoated particles. 
Correspondingly, the protamine-coated particles also showed a 10-fold increased 
capacity to stimulate the secretion of IFN-γ (Fig. 2B) as well as the proliferation of 
antigen-specific T cells (Fig. 2C). This effect of protamine was also observed when 
compared to stimulation of splenocytes using DCs pulsed with soluble OVA. Cells 
stimulated with 100 μg/ml or 10 μg/ml OVA solution produced very low or even 
undetectable levels of IL-2, and moderate and concentration-dependent T-cell 
proliferation. Unloaded microparticles, with or without the protamine coating, did neither 
stimulate IL-2 production nor lymphocyte proliferation (data not shown). 
 
  
Fig. 2. In vitro stimulation of OVA specific T cells. Bone-marrow derived DCs from 
BALB/c mice were pulsed for 3 h with different amounts of OVA-loaded microparticles 
and then incubated with splenocytes from DO11.10 mice in tripiclates. After 20 h, IL-2 
(A), and after 48 h, IFN-γ (B) was measured in the supernatants, and cell proliferation 
was determined by [3H] thymidine incorporation (C). Data was analysed by Two Way 
ANOVA with Bonferroni post test (***p < 0.0001; **p < 0.01). 
 
3.4. Stimulation of T-cell responses in mice 
The capacity of microparticles to enhance the induction of T-cell responses in vivo was 
evaluated in transgenic OT-II mice. Animals were injected with 1 mg of either uncoated 
or protamine-coated microparticles containing OVA protein, OVA-MP or OVA-
MP/protamine, and T-cell responses were assessed by measuring the activated CD4 T 
cells producing IFN-γ after 7, 14 and 21 days. Mice injected with OVA-MP/protamine 
induced higher frequencies of IFN-γ producing CD4 T cells at all time points as 
compared to mice that received OVA-MP (Fig. 3). As early as day 7 (Fig. 3A) the 
protamine-coated microparticles induced significant levels of IFN-γ producing cells, in 
contrast to the uncoated microparticles that needed an additional week to raise a 
moderate response. At day 14, less than 2% of the cells from the mice immunised with 
the uncoated particles were IFN-γ producing CD4 T cells as compared to 3% achieved 
with the protamine-coated particles (Fig. 3B). Maximal response was attained with both 
formulations at day 14 after the injection (Fig. 3B). Untreated mice were used to 
determine the background levels of IFN-γ in the OT-II mice. 
 
 
 
Fig. 3. In vivo induction of T-cell responses. OT-II mice were immunised with 
microparticles containing OVA (n = 5), and the percentage of IFN-γ producing CD4 T 
cells in peripheral blood was measured by flow cytometry after 7 (A), 14 (B) and 21 (C) 
days. Untreated mice were used as negative controls. Data were analysed by One Way 
ANOVA with Tukey's Multiple Comparison Test (***p < 0.0001; **p < 0.01; *p < 0.05). 
 
3.5. Stimulation of B-cell responses in mice 
To evaluate the effect of the protamine coating on the stimulation of B-cell responses, 
CBA/J mice were immunised with microparticles containing the major bee venom 
allergen PLA2. The antibody responses were determined at 28, 55 and 84 days after 
the first injection. After the first injection, the protamine-coated particles induced a weak 
PLA2-specific IgG1 response, while the uncoated particles failed to do so, as measured 
28 days after the priming (Fig. 4A). When a second dose was administered at day 28, 
the IgG1 response was strongly boosted by the protamine-coated particles, but not by 
the uncoated particles. The IgG1 levels remained high for at least 84 days. Two 
injections were required to induce a detectable IgG2a response; and again, the 
response, although weak, was stronger in mice immunised with the protamine-coated 
particles (Fig. 4B). 
 
 
 
Fig. 4. In vivo stimulation of humoral responses. CBA/J mice were immunised at day 0 
and boosted at day 28 with PLA2-containing microparticles, with or without protamine 
coating (A,B), and admixed with CpG (C,D) (n = 4). Blood was collected at days 28, 55 
and 84, and analysed by ELISA for anti-PLA2 IgG1 (A,C) and IgG2a (B,C) antibodies. 
The absorbance at 1/800 serum dilution was chosen for comparing the groups at each 
time point. Data were analysed by One Way ANOVA with Tukey's Multiple Comparison 
Test (***p < 0.0001; **p < 0.01; *p < 0.05). 
 
For assessing whether the observed benefit of the protamine coating persisted in the 
presence of an additional adjuvant, the two PLA2-loaded microparticle formulations 
were admixed with immune stimulatory CpG prior to injection. The previously observed 
Th2-biased response was shifted in the presence of CpG towards Th1, with both PLA2-
MP and PLA2-MP/protamine (Fig. 4C and D). The IgG1 levels increased for both 
formulations, but the protamine-coated particles again stimulated stronger responses 
than the uncoated particles. 
4. Discussion 
Microparticles of PLGA have been widely studied for their use as drug and antigen 
delivery systems [3], [31] and [6]. These particulate systems are able to deliver drugs or 
antigens such as DNA, proteins, and peptides over prolonged periods of time, and 
induce strong immune responses against encapsulated antigens [13], which makes 
them attractive candidates for vaccine development. 
Stability issues with encapsulated biologicals have led to an alternative method for 
associating antigens and DNA with PLGA microparticles, namely by adsorbing the 
bioactive materials onto the surface of anionic or cationic particles [16] and [18]. Yet, not 
many studies have addressed the question if and to what extent the modified particle 
surface itself influences the induction of immune responses in vivo. In the current study, 
we investigated the immunological effects of coating PLGA microparticles with the 
cationic electrolyte protamine for stimulation of humoral and cellular immune responses 
to various antigens. 
In mice immunised with microparticles containing the bee venom major allergen PLA2, 
we found that protamine-coated particles were more immunogenic than uncoated 
particles and enhanced the induction of long-lasting IgG1 antibody responses. In mice, 
the IgG1 subclass is associated with Th2 responses and is important to fight 
extracellular pathogens. In contrast, IgG2a is associated with Th1 and cytotoxic T-cell 
responses that are essential for inflammatory processes and in controlling intracellular 
pathogens. Although the protamine-coated particles also stimulated stronger IgG2a 
antibody responses than the uncoated microparticles, the overall IgG2a/Th1 response 
was weak, but could be strongly improved by admixing immunostimulatory CpG; in the 
presence of CpG, protamine-coated microparticles promoted again a stronger immune 
response than the uncoated particles. This capacity of polarising the immune responses 
towards Th1 or Th2, as a function of the co-formulation with immune response 
modifiers, may be exploited for different vaccination strategies, depending on the 
desired outcome [32]. 
The improved humoral immune responses after immunisation with the protamine-coated 
microparticles prompted us to study whether protamine also affected the stimulation of 
T cells. Indeed, enhanced T-cell responses to ovalbumin were observed in mice after 
using OVA-containing particles coated with protamine. Although, differences were not 
as striking as for the humoral responses, there was a significant increase in the 
percentage of IFN-γ producing CD4 T cells at all time points examined when compared 
to the uncoated particles. The enhanced immunogenicity of the protamine-coated 
particles was mediated through their preferential interaction with professional antigen-
presenting cells. Bone-marrow derived DCs pulsed with protamine-coated 
microparticles stimulated antigen-specific T cells in vitro more efficient than did DCs 
pulsed with uncoated microparticles. 
One potential reason for the difference between protamine-coated and protamine-free 
particles with respect to their interaction with APCs could be differences in the particles 
size distribution of the formulations. In this study, the size distribution of the uncoated 
OVA-containing microparticles was ideal for uptake, since 90% of the particles were 
smaller than 6.4 μm, and only particles smaller than 5–10 μm have been shown to be 
efficiently taken up by antigen-presenting cells [7] and [33]. However, as the protamine-
coated microparticles had a broader size distribution than the uncoated ones, with only 
50% of the particles being smaller than 7.2 μm, the size cannot explain the differences 
in vitro and in vivo immune responses. 
Besides particle size, particle surface charge may also influence the interaction with 
APCs. Positively charged particles are more likely to bind to the negatively charged cell 
surfaces, and thereby facilitate uptake and stimulation of immune responses. Indeed, 
cationic microparticles have been reported to enhance phagocytosis by DCs and 
macrophages in comparison with unmodified particles [34], [35] and [36]. The 
mechanism suggested for the enhanced uptake in those studies is the electrostatic 
attraction between the positively charged microparticles and the negatively charged cell 
surface mediating binding and subsequent internalisation. In addition to its positive 
charge at physiological pH, protamine specifically contains arginine-rich sequences, 
which share structural similarity with certain viral proteins such as the Tat from the 
Human Immunodeficiency Virus (HIV-1) or the VP22 from the Herpes Simplex Virus, 
both of which possess protein translocation activity [37], [38] and [39]. These sequences 
of basic amino acids mediate the penetration of viruses into cells in an energy-
independent manner [40]; thus, these so-called cell-penetrating peptides or peptidic 
moieties appear to be particularly good candidates as transporters for drug delivery. 
While the cell-penetrating property of Tat peptides have been extensively studied [41], 
[42] and [43], the potential of protamine to carry cargos across the cell membrane is 
less recognised. However, in 2005, two independent groups reported that protamine 
can act as an efficient membrane-translocating peptide both in vitro [44] and in vivo [44] 
and [45]. Park et al. showed that a protein toxin conjugated to protamine was able to 
translocate into cells in vitro, resulting in the inhibition of tumour growth in vivo. It was 
also reported that Tat-carrying [46] and protamine-carrying [44] iron nanoparticles were 
readily internalised by cells. Moreover, Tat-liposomes of 200 nm showed potential for 
intracellular gene delivery in vitro and in vivo [47]and [48]. These experiments suggest 
that the improved immunological performance of protamine-coated antigen-containing 
PLGA microparticles was mediated by the cell-penetrating properties of the arginine-rich 
protamine. We could confirm this by testing the transfection of bone-marrow DCs using 
microparticles containing a plasmid coding for GFP (data not shown). However, to test 
this hypothesis in a more stringent model, we also tested the uptake in and transfection 
of non-phagocytic HEK cells. Indeed, protamine-coated particles were capable to 
transfect the HEK cells, whereas uncoated particles did not possess this capacity. The 
same was observed when testing the particles on non-phagocytic melanoma cells (no 
shown). As the size distribution of the tested formulations was almost identical 
(± 0.3 μm), the observed differences must be ascribed to protamine and its ability to 
translocate the microparticles intracellularly. 
Although, there is certain controversy in the literature concerning the translocation 
mechanisms of cell-penetrating peptides, recent data suggests more than one 
mechanism. Studies using Tat-nanoparticles or Tat-liposomes suggest that the 
translocation mechanism occurs via energy-dependent macropinocytosis [43] and [49], 
whereas peptide-conjugated small molecules penetrate via electrostatic interactions and 
do not seem to depend on energy [50]. The exact mechanism of protamine-mediated 
penetration of microparticles into non-phagocytic cells remains to be clarified. 
Taken together, we have shown the increased immunogenicity of antigens 
encapsulated in protamine-coated PLGA microparticles as compared to uncoated 
particles and proposed a possible mechanism of action. Further research to 
characterise protamine-coated particles is required to develop further a new technology 
combining the advantages of microparticles for prolonged antigen release and 
protamine for facilitating cell penetration of the delivery system. The potential 
applications of such an intracellular delivery system technology may span the areas of 
vaccine development, cancer immunotherapy, and gene/protein delivery. 
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